Literature DB >> 2113413

alpha-Methyl-p-tyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation.

K J Axt1, D L Commins, G Vosmer, L S Seiden.   

Abstract

Depletion of brain dopamine (DA) by pretreatment with the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine (AMT) has been shown to prevent the long-term neurotoxic effects of methamphetamine (MA). In addition, it has recently been reported that the neurotoxins 6-hydroxydopamine (6-OHDA) and 5,6-dihydroxytryptamine (5,6-DHT) are formed endogenously in neostriatum and hippocampus, respectively, following a single neurotoxic dose of MA. We, therefore, have examined the ability of AMT pretreatment to prevent the MA-induced formation of 6-OHDA and 5,6-DHT. We report that AMT pretreatment significantly decreases the frequency with which 6-OHDA and 5,6-DHT are detected following MA administration. Neurotoxin formation is compared with brain levels of DA and 5-hydroxytryptamine (5-HT) 2 weeks after MA administration. It is concluded that the ability of AMT to attenuate both 6-OHDA formation and long-term depletions of DA is due to a decrease in the MA-releasable pool of DA. The effect of AMT on MA-induced depletions of 5-HT is less clear and may involve additional factors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113413     DOI: 10.1016/0006-8993(90)90606-c

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

Authors:  L S Seiden; R Lew; J E Malberg
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

2.  Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism.

Authors:  C Saunders; J V Ferrer; L Shi; J Chen; G Merrill; M E Lamb; L M Leeb-Lundberg; L Carvelli; J A Javitch; A Galli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.

Authors:  F Fumagalli; R R Gainetdinov; Y M Wang; K J Valenzano; G W Miller; M G Caron
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

4.  Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis.

Authors:  Kristin E Larsen; Edward A Fon; Teresa G Hastings; Robert H Edwards; David Sulzer
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 5.  Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

Authors:  G Huether; D Zhou; E Rüther
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  Chronic methamphetamine-induced neurodegeneration: Differential vulnerability of ventral tegmental area and substantia nigra pars compacta dopamine neurons.

Authors:  Yijuan Du; You Bin Lee; Steven M Graves
Journal:  Neuropharmacology       Date:  2021-10-02       Impact factor: 5.250

7.  Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity.

Authors:  J F Marshall; S J O'Dell; F B Weihmuller
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 8.  Methamphetamine toxicity and messengers of death.

Authors:  Irina N Krasnova; Jean Lud Cadet
Journal:  Brain Res Rev       Date:  2009-03-25

9.  Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter.

Authors:  F Fumagalli; R R Gainetdinov; K J Valenzano; M G Caron
Journal:  J Neurosci       Date:  1998-07-01       Impact factor: 6.167

10.  Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.

Authors:  Thomas S Guillot; Kennie R Shepherd; Jason R Richardson; Min Z Wang; Yingjie Li; Piers C Emson; Gary W Miller
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.